cervical-cancer-treatment-market

Cervical Cancer Treatment Market By Product (Chemotherapy, Targeted Therapy, Surgical Procedure, Radiation Therapy and Others) - Growth, Future Prospects & Competitive Analysis, 2024 – 2032

13 Jan 2019 Format PDF icon PPT icon XLS icon Request Sample

The cervical cancer treatment market will be highlighting excellent growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2023 to 2030. Cervical cancer occurs in women in age group ranging from 14 to 49 years. The human papillomavirus (HPV) is the main causative agent for the occurrence of cervical cancer which is sexually transmitted. Cervical cancer can be prevented by performing early screening test and vaccination using Gardasil against HPV infection.

It is quite obvious that generic market is having the major economic share in the cervical cancer treatment market, however the advent of biologics in the form of monoclonal antibodies and biosimilars has resulted in a major paradigm shift in the treatment regimen. Z-100 and ADXS11-001 are currently in the phase III clinical trials being tested for drug safety and efficacy in the treatment of cervical cancer.

"Affordable reimbursement scenario drive the chemotherapy market growth"

Currently, chemotherapy is reigning the product segment for cervical cancer treatment market. Drugs such as cisplatin, carboplatin, paclitaxel, doxorubicin and gemcitabine are employed for the treatment of cervical cancer in advanced stages. Radiation therapy such as external beam therapy and brachytherapy are given concurrently with chemotherapy in some stages of cervical cancer to give excellent synergistic effect. The side effects associated with both the therapy are severe thereby leading to the need for targeted drug therapy. Avastin (bevacizumab) and Keytruda (pembrolizumab) etc. are used in cancer immunotherapy which possesses impressive clinical efficacy, dose tolerance and patient compliance. Targeted drug therapy will be the fastest growing market during the forecast period owing to the strong drug pipeline in phase III clinical trials such as nimotuzumab and Atezolizumab. Cervical hysterectomy involves the removal of uterus, cervix and sometimes the fallopian tubes in women suffering with early stage cervical cancer.

"Increasing number of patients screened for cervical cancer drive the market growth in North America"

North America is the clear leader for the geographical segment in the cervical cancer treatment market. As per the latest research findings of American Cancer Society, in 2019, approximately 13,170 new cases were diagnosed for cervical cancer and around 4,250 women will die from cervical cancer. Rising prevalence of cervical cancer and increasing public health awareness resulting in early screening and medical intervention drives the market growth in North America. According to the facts presented by World Health Organization (WHO) it is estimated that in 25,000 women for the European region will die from cervical cancer. Existence of major players such as Merck & Co., Inc., F.Hoffman La-Roche AG, GlaxoSmithkline Plc., etc. propel the cervical cancer market growth in the European region. Asia Pacific will register outstanding growth during the forecast period owing to the proactive government policies in early screening and medical intervention to curb the mortality related to cervical cancer and presence of huge generic market.

Biopharmaceutical companies having a strong foothold in the cervical cancer treatment market are, Allergan, Plc., Biocon Ltd., CooperSurgical, Inc., Eli Lilly & Company, F.Hoffman La-Roche AG, GlaxoSmithkline Plc., Ethicon, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Varian Medical Systems, Inc. 

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cervical Cancer Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Cervical Cancer Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Product
  • Chemotherapy
  • Targeted Therapy
  • Surgical Procedure
  • Radiation Therapy
  • Others

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Cervical Cancer Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Cervical Cancer Treatment market?
  • Which is the largest regional market for Cervical Cancer Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Cervical Cancer Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Cervical Cancer Treatment market worldwide?
Choose Licence Type
$4325
$6325
$12650
Why Acute
View Other Reports